ZA9811434B - Protein expression in baculovirus vector expression systems - Google Patents

Protein expression in baculovirus vector expression systems

Info

Publication number
ZA9811434B
ZA9811434B ZA9811434A ZA9811434A ZA9811434B ZA 9811434 B ZA9811434 B ZA 9811434B ZA 9811434 A ZA9811434 A ZA 9811434A ZA 9811434 A ZA9811434 A ZA 9811434A ZA 9811434 B ZA9811434 B ZA 9811434B
Authority
ZA
South Africa
Prior art keywords
expression
baculovirus vector
systems
protein expression
protein
Prior art date
Application number
ZA9811434A
Other languages
English (en)
Inventor
Dietmar Kretzdorn
Dirk Fransiscus Marinus V Wiel
Abraham Johannes De Smit
Robertus Jacobus Mari Moormann
Erik Kees Hamann
Original Assignee
Stichting Inst Dierhouderij
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8229076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9811434(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Inst Dierhouderij, Bayer Ag filed Critical Stichting Inst Dierhouderij
Publication of ZA9811434B publication Critical patent/ZA9811434B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA9811434A 1997-12-18 1998-12-14 Protein expression in baculovirus vector expression systems ZA9811434B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97203989A EP0924298A1 (en) 1997-12-18 1997-12-18 Protein expression in baculovirus vector expression systems

Publications (1)

Publication Number Publication Date
ZA9811434B true ZA9811434B (en) 1999-06-16

Family

ID=8229076

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811434A ZA9811434B (en) 1997-12-18 1998-12-14 Protein expression in baculovirus vector expression systems

Country Status (22)

Country Link
US (2) US6555346B1 (xx)
EP (2) EP0924298A1 (xx)
JP (2) JP4220126B2 (xx)
KR (3) KR100682171B1 (xx)
CN (2) CN101130073A (xx)
AR (1) AR015499A1 (xx)
AT (1) ATE324456T1 (xx)
AU (1) AU750514B2 (xx)
BR (1) BR9813692B1 (xx)
CA (2) CA2315248C (xx)
CO (1) CO4820445A1 (xx)
DE (1) DE69834346T2 (xx)
DK (1) DK1049788T3 (xx)
ES (1) ES2267203T3 (xx)
HK (1) HK1037670A1 (xx)
HU (1) HU228122B1 (xx)
IL (2) IL136815A0 (xx)
NZ (1) NZ505322A (xx)
TW (1) TWI225094B (xx)
UY (1) UY25315A1 (xx)
WO (1) WO1999031257A2 (xx)
ZA (1) ZA9811434B (xx)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
EP1035205A1 (en) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
CN1338310A (zh) * 2000-08-10 2002-03-06 清华大学 一种猪瘟病毒表位疫苗及其制备方法
AU2002248557A1 (en) * 2001-03-05 2002-09-19 Transtech Pharma, Inc. High level insect expression of rage proteins
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US7803777B2 (en) * 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
WO2004091499A2 (en) * 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
JP4674702B2 (ja) * 2003-04-09 2011-04-20 バイオジェネリクス エージー グリコペギレ−ション法およびその方法により生成されたタンパク質／ペプチド
MXPA05011832A (es) 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055946A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
CA2552892C (en) * 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
NZ551335A (en) 2004-06-18 2010-03-26 Ambrx Inc Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
WO2006073846A2 (en) 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
NZ584597A (en) 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
BRPI0516385B1 (pt) 2004-12-22 2021-07-20 Ambrx, Inc. Composto ou sal do mesmo contendo aminoácidos não naturais e polipeptídeos, métodos para produção e derivatização de um polipeptídeo
WO2006074279A1 (en) * 2005-01-06 2006-07-13 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
WO2006078645A2 (en) * 2005-01-19 2006-07-27 Neose Technologies, Inc. Heterologous polypeptide expression using low multiplicity of infection of viruses
US20060246544A1 (en) * 2005-03-30 2006-11-02 Neose Technologies,Inc. Manufacturing process for the production of peptides grown in insect cell lines
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
MX2007015058A (es) 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
MX2008002395A (es) * 2005-08-19 2008-03-18 Neose Technologies Inc Factor vii y factor viia glicopegilados.
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) * 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
CN100497612C (zh) * 2006-01-25 2009-06-10 中国农业科学院生物技术研究所 一种耐高温乳糖酶的制备方法
CU23544A1 (es) 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
PT2061878E (pt) 2006-09-08 2014-04-22 Ambrx Inc Supressor híbrido arnt para células de vertebrados
JP2010505874A (ja) * 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
EP2076533B1 (en) 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
EP2162535A4 (en) * 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
MX2009013259A (es) * 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101152570B (zh) * 2007-10-19 2010-11-24 清华大学 一种猪瘟病毒表位疫苗及其制备方法
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
TWI362416B (en) * 2008-07-31 2012-04-21 Mao Xing Biolog Technology Co Ltd Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
AU2009296397B2 (en) 2008-09-26 2012-11-08 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP2202298A1 (en) 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011291943B2 (en) 2010-08-17 2015-01-22 Ambrx, Inc. Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2748612B1 (en) * 2011-08-24 2017-09-20 Zoetis Services LLC Improved vaccine diagnostics
CN105392362B (zh) * 2012-06-12 2018-11-09 替代基因表达公司 用于在宿主昆虫中表达重组蛋白的杆状病毒dna元件
US9982239B2 (en) * 2012-06-12 2018-05-29 Alternative Gene Expression S.L. Baculoviral DNA elements for the expression of recombinant proteins in a host cell
US9487971B2 (en) 2013-03-15 2016-11-08 Spectrum Brands, Inc. Electro-mechanical locks with bezel turning function
DE102013103336A1 (de) * 2013-04-03 2014-10-09 B. Braun Avitum Ag Vorrichtung zur Identifizierung einer Dialysatorvorrichtung oder einer Komponente derselben, und hierfür verwendbare Sensorvorrichtung
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
EP3039127B1 (en) * 2013-08-30 2020-01-01 GlaxoSmithKline Biologicals S.A. Large scale production of viruses in cell culture
CN103882051B (zh) * 2014-03-20 2016-04-06 北京市农林科学院 一种检测猪瘟病毒抗体的elisa方法及检测试剂盒
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
KR20170083249A (ko) * 2016-01-08 2017-07-18 경상대학교산학협력단 곤충세포를 이용한 식물 유래 오스모틴 단백질의 대량 생산 방법
MY193457A (en) 2017-02-08 2022-10-14 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JP2021528959A (ja) 2018-06-22 2021-10-28 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 細胞内で存続する遺伝子送達のためのベクター
CN109182380B (zh) * 2018-08-14 2022-06-03 浙江大学 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
CN112646840B (zh) * 2020-12-25 2022-11-18 石河子大学 一种杆状病毒表达系统制备牛病毒性腹泻病毒e2蛋白的方法及应用
WO2023009968A1 (en) * 2021-07-28 2023-02-02 Biomarin Pharmaceutical Inc. Large scale adeno-associated virus production systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5514634A (en) 1991-11-06 1996-05-07 Mobil Oil Corporation High activity polyethylene catalysts
HU220746B1 (hu) * 1994-06-17 2002-05-28 Instituut Voor Veehouderij En Diergezondheid Pestivírustörzsekből izolált nukleotidszekvenciák, az általuk kódolt polipeptidek és ezek alkalmazása pestivírus-fertőzések diagnosztizálására és megelőzésére
ATE206458T1 (de) * 1994-12-20 2001-10-15 Akzo Nobel Nv T-zellen stimulierendes protein von pestivirus
AU720337B2 (en) * 1995-02-17 2000-05-25 Stichting Dienst Landbouwkundig Onderzoek Production of biologically active recombinant bovine follicle stimulating hormone (REC bFSH) in the baculovirus expression system
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems

Also Published As

Publication number Publication date
KR20010033304A (ko) 2001-04-25
DK1049788T3 (da) 2006-08-28
HUP0101136A2 (hu) 2001-08-28
BR9813692A (pt) 2001-11-13
AR015499A1 (es) 2001-05-02
US6919085B2 (en) 2005-07-19
US6555346B1 (en) 2003-04-29
IL181468A0 (en) 2007-07-04
CA2315248A1 (en) 1999-06-24
CN101130073A (zh) 2008-02-27
BR9813692B1 (pt) 2011-03-09
DE69834346T2 (de) 2007-04-19
IL181468A (en) 2010-12-30
KR20050115340A (ko) 2005-12-07
JP4336723B2 (ja) 2009-09-30
KR100699609B1 (ko) 2007-03-27
HUP0101136A3 (en) 2010-01-28
CO4820445A1 (es) 1999-07-28
HK1037670A1 (en) 2002-02-15
TWI225094B (en) 2004-12-11
CA2635158A1 (en) 1999-06-24
EP0924298A1 (en) 1999-06-23
ES2267203T3 (es) 2007-03-01
AU1786599A (en) 1999-07-05
HU228122B1 (en) 2012-11-28
NZ505322A (en) 2003-02-28
JP4220126B2 (ja) 2009-02-04
JP2003533964A (ja) 2003-11-18
WO1999031257A2 (en) 1999-06-24
KR100682171B1 (ko) 2007-02-12
WO1999031257A3 (en) 1999-08-26
US20040028701A1 (en) 2004-02-12
CN1283801C (zh) 2006-11-08
CA2315248C (en) 2008-10-14
EP1049788A2 (en) 2000-11-08
KR100796871B1 (ko) 2008-01-22
JP2007254482A (ja) 2007-10-04
DE69834346D1 (en) 2006-06-01
CN1295620A (zh) 2001-05-16
KR20050115341A (ko) 2005-12-07
UY25315A1 (es) 1999-09-27
EP1049788B1 (en) 2006-04-26
IL136815A0 (en) 2001-06-14
ATE324456T1 (de) 2006-05-15
AU750514B2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
IL136815A0 (en) Protein expression in baculovirus vector expression systems
GB9718609D0 (en) Fusion protein
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
EP1018551A4 (en) MEGSINE PROTEIN
GB9718110D0 (en) Peptides
ZA985999B (en) Protein kinases and uses thereof
EP1012262A4 (en) HFLP PROTEIN HFLP
GB9701710D0 (en) Mammalian protein
ZA984322B (en) Sucrose-binding proteins
GB9700154D0 (en) Peptides
GB9715064D0 (en) Protein expression
PL339259A1 (en) Gonadothropin expression in dictostelium
GB9720784D0 (en) Protein
EP0996457A4 (en) PEPTIDES RELEASERS OF F.S.H.
GB2334257B (en) Rectroviral vectors
GB2331752B (en) Vectors
GB9720633D0 (en) BHV-2 vector
GB9719670D0 (en) Protein
GB9720785D0 (en) Protein
GB9703103D0 (en) Protein
GB9722727D0 (en) Proteins
GB9722003D0 (en) Proteins
GB9707822D0 (en) Proteins
GB9703104D0 (en) Proteins